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Abstract
Autism spectrum disorders (ASDs) have garnered significant attention as an important grouping of developmental brain
disorders. Recent genomic studies have revealed that inherited or de novo copy number variations (CNVs) are significantly
involved in the pathophysiology of ASDs. In a previous report from our laboratory, we generated mice with CNVs as a model
of ASDs, with a duplicated mouse chromosome 7C that is orthologous to human chromosome 15q11-13. Behavioral
analyses revealed paternally duplicated (patDp/+) mice displayed abnormal behaviors resembling the symptoms of ASDs. In
the present study, we extended these findings by performing various behavioral tests with C57BL/6J patDp/+ mice, and
comprehensively measuring brain monoamine levels with ex vivo high performance liquid chromatography. Compared with
wild-type controls, patDp/+ mice exhibited decreased locomotor and exploratory activities in the open field test, Y-maze
test, and fear-conditioning test. Furthermore, their decreased activity levels overcame increased appetite induced by
24 hours of food deprivation in the novelty suppressed feeding test. Serotonin levels in several brain regions of adult patDp/
+ mice were lower than those of wild-type control, with no concurrent changes in brain levels of dopamine or
norepinephrine. Moreover, analysis of monoamines in postnatal developmental stages demonstrated reduced brain levels
of serotonin in young patDp/+ mice. These findings suggest that a disrupted brain serotonergic system, especially during
postnatal development, may generate the phenotypes of patDp/+ mice.
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Introduction
Autism is a widely accepted neurodevelopmental disorder
characterized by several major criteria, including impairments in
social interaction, verbal and non-verbal communication difficul-
ties, repetitive or rigid behavior, and restricted interest [1]. Autism
spectrum disorders (ASDs) comprise autistic disorder, Rett’s
disorder, Asperger’s disorder,and pervasive developmental disorder
not otherwise specified (PDD-NOS) in DSM-IV. The prevalence of
ASDs was recently estimated to have increased to 1 in 166 births
[2]. According to previous studies of twins, these disorders are
highly heritable because concordance rates for monozygotic twins
(70–90%) are several fold higher than the corresponding rates for
dizygotic twins (0–10%) [3]. Although there are many candidate
genes for pathophysiology in ASDs, recent high-resolution genetic
techniques revealed that a de novo copy number variation (CNV) is
also a significant risk factor for ASDs, and is a more important risk
factor than previously recognized [4].
In several candidate chromosomal regions with relevance for
ASDs, duplication of human chromosome 15q11-13 is the most
frequent chromosome rearrangement, found in 1–4% of ASDs
patients [5]. Moreover, this region is an imprinting region where
deletions or methylation abnormalities of paternal and maternal
alleles leads to Prader-Willi syndrome and Angelman syndrome,
respectively. In chromosomal duplication, these imprinting effects
can also affect the resulting phenotypes. Maternal duplication of
human chromosome 15q11-13 is believed to cause ASDs, whereas
paternal duplication usually results in a normal behavioral
phenotype [6]. However, recent findings suggest that maternal
interstitial duplications may be less prevalent than previously
assumed [7], and indeed paternal duplication of this region may
lead to autistic-like behavior [7].
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iology of ASDs. Notably, serotonin (5-HT) concentrations in
platelets of patients with ASDs are higher and more widely
distributed than those of controls [8,9]. However, this abnormality
may not result in abnormal brain 5-HT levels because 5-HT
generally does not penetrate the blood brain barrier (BBB).
Nevertheless, a recent report showed that 5-HT could cross the
BBB in rats [10]. Thus, the relationship between peripheral and
central 5-HT in ASDs remains unclear, and might be more
complex than established mechanisms would indicate. As further
evidence for 5-HT abnormality in ASDs, administration of
selective serotonin reuptake inhibitors (SSRIs) improved repetitive
behavior which is a core symptom in ASDs [11].
In previous studies from our laboratory, using a chromosome-
engineering technique, we generated mice with a 6.3 Mb
duplication on mouse chromosome 7 that corresponds to human
chromosome 15q11-13 [12,13]. Furthermore, we found that
patDp/+ mice with a duplicated region derived from a paternal
allele displayed several abnormal behavioral similarities to autistic
phenotypes in two different strains, 129S6/SvEvTac (129S6) and
C57BL/6J. However, no significant change has been observed on
these behavioral tests for maternally duplicated (matDp/+) mice
compared with wild-type (WT) mice [13]. In the present study, we
conducted a comprehensive battery of behavioral tests in C57BL/
6J patDp/+ mice to evaluate other behavioral abnormalities.
Moreover, using ex vivo high performance liquid chromatography
(HPLC), we performed quantitative analyses of biogenic amines in
brains of adult and young mice to determine the role of brain
monoamines in any measured behavioral abnormalities. The
specific hypothesis tested was whether there is a relationship
between specific behaviors and brain monoamines in patDp/+
mice, and the results suggest that disturbance of serotonergic
signaling during development may cause abnormal behaviors in
these mice.
Results
Decreased exploratory activity of patDp/+ mice
The results of a comprehensive set of behavioral tests are
presented in Table S1. Compared with WT mice increased body
weight and lower temperature in patDp/+ mice was observed.
There is no difference between patDp/+ and WT mice in hot plate
test, tail suspension test, and prepulse inhibition test (Table S1).
Neuromuscular examination and rotarod experiments revealed
that patDp/+ mice possess normal motor coordination (Table S1).
To investigate the phenotypes of C57BL/6J patDp/+ mice, we
determined the circadian rhythms of locomotor activity in these
mice compared with WT controls. Circadian rhythms in patDp/+
mice warrant study because ASDs patients often exhibit
disturbances of circadian rhythms and sleep [14]. To determine
the free running periods of patDp/+ mice, subjects were initially
entrained for 2 weeks to a 12-hour light/dark cycle (LD) and then
kept in constant darkness condition (DD) for subsequent 2 weeks.
The circadian rhythm of locomotor activity in patDp/+ mice was
not significantly different from WT mice (Fig. 1A). In fact, the
circadian periods of locomotor activity displayed no significant
difference between these genotypes (t11=20.63, p.0.05, t-test,
data not shown). Recordings of basal locomotor activities in mice
entrained for 1 week indicated that patDp/+ mice exhibited
decreased movement, even when habituated in their home cages
Figure 1. patDp/+ mice have decreased basal locomotor activity in their home cages. (A) Representative activity records from a WT mouse
and a patDp/+ mouse. Light regimen: 17 d in LD followed by 15 d DD. (B) Activity difference during light phase (left) and dark phase (right) after 1
week in LD (p,0.01, 0.05, t-test, respectively). N=4 for WT and 9 for patDp/+. Error bars indicate SEM. **, p,0.01, *, p,0.05.
doi:10.1371/journal.pone.0015126.g001
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t1090=22.41, p,0.05, t-test). These results suggest that patDp/+
mice have spontaneously decreased locomotor activities and
normal circadian rhythms.
During the 120 min test period of the open field test, patDp/+
mice exhibited less distance traveled (Fig. 2B; F1,42=5.84;
p=0.02), less time spent in the center area accompanied by
thigmotaxis (Fig. 2A; averaged trace images of each genotype)
(Fig. 2C; time spent in center area; F1,42=11.61; p,0.01), and less
vertical activity (Fig. 2D; F1,42=10.12; p,0.01) compared with
WT mice. The ratio of center time/total distance for the first
30 min was also calculated as ‘‘anxiety index’’. patDp/+ mice
significantly showed the higher ratio than WT mice (Fig. 2E;
t42=2.2, p,0.05, t-test). These results suggest that patDp/+ mice
exhibited increased anxiety-like behavior and/or decreased
locomotor exploration in novel environments.
We used the novelty suppressed feeding test [15] to determine
whether patDp/+ mice exhibit anxiety-like behaviors or are the
lowered motivation caused by reduced activity. In this test, patDp/
+ mice had longer latencies to feed than WT mice (Fig. 3B).
Furthermore, most WT mice ate chow within 5 min, whereas
approximately 60% of patDp/+ mice did not (Fig. 3A). Kaplan-
Meier survival analysis and the Mantel-Cox log-rank test revealed
that this was a significant difference (p,0.01). The amount of food
consumed in the home cage after the test and body weight
decreased (%) by 24 h food deprivation were not significantly
different between patDp/+ and WT mice (t25=1.57, p=0.13, t-
test, for food consumed, t25=0.51, p=0.61 for body weight, data
not shown). These results indicate that patDp/+ mice have
increased anxiety-like behavior and/or decreased activity, even
when food deprivation opposes these effects.
Fear-like behavior was examined with the contextual and cued
fear conditioning test. In this test, freezing responses to a foot
shock in patDp/+ mice were similar to WT mice (Fig. 4A).
However, basal freezing rates of patDp/+ mice in any condition
tested, including both context and altered context with cues
conditioning, were significantly increased compared with WT
mice [Fig. 4A; F1,42=44.58; p,0.01, 4B; F1,42=16.25; p,0.01,
4C (pre-tone period); F1,42=8.49; p,0.01, (cued); F1,42=14.04;
p,0.01]. These results may suggest that patDp/+ mice displayed
fear-like behavior. Alternatively, since the basal freezing rates in
patDp/+ mice are substantially higher before stress conditioning,
these unusual phenotypes could represent decreased locomotor
activity and/or increased novelty-induced anxiety.
To examine exploratory behavior and working memory, we also
performed the Y-maze test in these subjects. The number of
Figure 2. patDp/+ mice display decreased exploratory activity in the open field test. (A) Averaged trace images from each genotype. (B)
Total distance traveled. (C) Time spent in the center area of the compartment. (D) Count of vertical activity. (B)–(D) Each data point represents the
mean value in a 5-min segment. N=22 for both genotypes. (E) The ratio of center time/total distance for the first 30 min was also calculated. Error
bars indicate SEM. **, p,0.01, *, p,0.05.
doi:10.1371/journal.pone.0015126.g002
Decreased Activity and 5-HT in patDp/+ Mice
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15126entries into each arm was significantly decreased in patDp/+ mice
compared with WT mice (Fig. 5A; t42=2.91; p,0.01). In contrast,
no differences in alternation rates were observed (Fig. 5B;
t42=20.95; p=0.35) over the 10-min test. These results suggest
that although working memory in patDp/+ mice is not impaired
they have decreased exploratory activity.
Marble burying behavior is regarded as a rodent model for
obsessive-compulsive disorder (OCD) or anxiety [16]. The
number of marbles buried in patDp/+ mice was significantly
reduced compared with WT mice (Fig. 6A; p,0.01, F1,39=7.63),
whereas no difference in locomotor activity between patDp/+ and
WT mice was observed (Fig. 6B; p=0.25, F1,39=1.39). These
results support that patDp/+ mice have decreased exploratory
activity.
Decreased 5-HT and 5-HIAA in the patDp/+ adult brain
To establish the relationship between brain neurochemistry and
behavioral disruptions in patDp/+ mice, we quantified levels of
biogenic monoamines ex vivo, including 5-HT and its major
metabolite 5-hydroxyindoleacetic acid (5-HIAA), using HPLC in
several adult brain regions. We specifically focused on 5-HT
because it is one of the most notable molecules for the
pathophysiology of ASDs [8,9]. Levels of 5-HT and 5-HIAA
were significantly decreased in several brain regions from patDp/+
mice (5-HIAA; OB, Ce, Mid, t18=2.72, 2.20, 2.99, p,0.05, 5-
HT; OB, Mid, t18=2.23, 2.67, p,0.05). In contrast, there was no
change in levels of the other monoamines, dopamine (DA) and
norepinephrine (NE), compared with WT mice in any brain
region. These findings suggest that the neurochemical differences
between patDp/+ and WT mice are specific for the serotonergic
system (Table 1). However, metabolic rates of 5-HT turnover,
determined from the ratio of 5-HIAA to 5-HT, in patDp/+ mice
were not altered compared with WT mice (Table 1), suggesting
that monoamine oxidase (MAO) functions at a similar rate in both
WT and patDp/+ adult mice. Collectively, these results demon-
strate alterations in the serotonergic system of patDp/+ mice that
may contribute to their behavioral phenotypes.
Disrupted developmental changes of 5-HT in patDp/+
mice
ASDs are thought to be developmental disorders, and there are
several neurodevelopmental disorders wherein subjects exhibit low
brain levels of biogenic amines [17]. Thus, we performed a
comprehensive investigation of brain monoamine levels in several
brain regions of mice from postnatal weeks 1 to 3. Two-way
ANOVA revealed that 5-HT concentrations in patDp/+ mice
tended to decrease in all brain regions tested over these
developmental stages (genotype effect) (Fig. 7; 5-HT and Table
Figure 3. patDp/+ mice show longer latencies to feed in a novel environment. (A) Latency to feed in a novel environment (Cum. Summ =
cumulative survival– i.e. the percentage of animals that have not eaten) (Kaplan-Meier survival analysis, Mantel-Cox log-rank test, p,0.01). (B)
Average latency to feed in a novel environment. N=14 for WT and 13 for patDp/+. Error bars indicate SEM. **, p,0.01.
doi:10.1371/journal.pone.0015126.g003
Figure 4. patDp/+ mice have higher basal freezing rates in the fear-conditioning test. (A) Immediate freezing during the fear-conditioning
phase. Arrows and bars indicate unconditional stimuli (foot shock, 2 sec) and conditioned stimuli (white noise, 30 sec), respectively. (B) Contextual
testing conducted 24 h after fear conditioning. (C) Cued test with altered context and pre-tone period are shown. N=22 for both genotypes. Error
bars indicate SEM. **, p,0.01.
doi:10.1371/journal.pone.0015126.g004
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(HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) tended to
increase over these developmental stages in some brain regions of
patDp/+ mice, such as the pons and medulla (Fig. 7; DA, DOPAC,
HVA and Table S2). Conversely, brain levels of NE and its
metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) did not
consistently increase or decrease over these developmental stages
in patDp/+ mice (Table S2). These results suggest that 5-HT
signaling in the brains of patDp/+ mice is altered during these
developmental stages.
Discussion
Major autistic phenotypes such as impaired social interaction in
the 3-chamber sociability test and perseverative responding in
reversal learning tests have been reported in patDp/+ mice from
either the C57BL/6J or 129S6 strains [13]. In the present study,
we report additional behavioral abnormalities of C57BL/6J
patDp/+ mice. When conducting daily breeding procedures with
these animals, we observed decreased movements and behavior. In
support of this observation, patDp/+ mice exhibited decreased
exploratory activity in the open field test. Furthermore, this
abnormal phenotype was observed in other behavioral tests, such
as the Y-maze test. Collectively, these findings strongly suggest that
patDp/+ mice have decreased exploratory activity. In an
evaluation of the underlying causes of decreased exploratory
activity in patDp/+ mice, motor tests showed that patDp/+ mice
possess normal motor coordination. This excludes the possibility
that decreased exploratory activity in these animals resulted from
dysfunctional motor coordination. Furthermore, lower exploratory
activity in patDp/+ mice overcame increased appetite induced by
24 hours of food deprivation. As another example, in the marble
burying test, patDp/+ mice buried significantly fewer marbles than
WT mice, but no difference in locomotor activity between patDp/+
and WT mice were observed. These results further suggest that
decreased activity in patDp/+ mice may be elicited by anxiety
induced by novel environmental conditions. However, decreased
activity in patDp/+ mice was observed in their home cages and no
significant differences were observed in the elevated plus maze test.
Regarding these discrepancies, it is important to note that these
measures are not inherently correlated and may reflect unique
aspects of anxiety-like behaviors [18,19]. However, reduced
locomotor activity in the open field test was not reported in
129S6 mice [13]. This may be due to lower levels of spontaneous
locomotor activity in 129S6 mice compared with C57BL/6J [20].
Interestingly, longer latencies to approach food during either
eight-arm radial maze or T-maze tests have been observed in
129S6 mice [13]. Taken together, these findings indicate that the
patDp/+ phenotype includes decreased exploratory activity,
increased fear, or decreased motivation. In addition, patients with
Figure 5. patDp/+ mice show decreased exploratory activity in Y-maze test. (A) The number of entries into each arm. (B) Percentage of
traveled arm alterations. N=22 for both genotypes. Error bars indicate SEM. **, p,0.01.
doi:10.1371/journal.pone.0015126.g005
Figure 6. patDp/+ mice show less marble burying behavior. (A) The number of marbles buried for 30 min (p,0.01, F1,39=7.63). The marble
buried was defined as over 50% marble covered by bedding material. (B) Total distance traveled (p=0.25, F1,39=1.39). N=19 for WT, 22 for patDp/+
mice. Error bars indicate SEM. *, p,0.01.
doi:10.1371/journal.pone.0015126.g006
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coordination problems [7]. The mouse cerebellum is involved in
exploratory behavior and motivational processes [21], and
reduced exploration and stereotyped behavior in children with
autism is linked with cerebellar hypoplasia [22]. Thus, the
cerebellum of patDp/+ mice provides an intriguing target for
further study.
In addition to abnormal monoamine concentrations in the
cerebellum, we found decreased levels of both 5-HT and 5-HIAA
in several brain regions of adult patDp/+ mice and decreased levels
of 5-HT during developmental stages from postnatal weeks 1 to 3
in all brain regions tested. The alterations in young mice were
more prominent than the alterations in adult mice, suggesting that
abnormalities of 5-HT signaling during childhood may contribute
to the etiology of abnormal adult behaviors. Supporting this
hypothesis, treating mice with SSRIs during postnatal days 4–21
influenced behavioral abnormalities (decreased exploratory activ-
ity in open field and elevated plus maze test, increased anxiety,
depression related behaviors using novelty suppressed feeding,
novelty induce hypophagia and shock escape test) when animals
reached adulthood, and these abnormalities were not observed
when adult animals were treated with SSRIs [23,24]. Accordingly,
5-HT levels during childhood can influence adult behaviors and
may contribute to abnormal behaviors in patDp/+ mice.
In the context of ASDs, 5-HT is the most well established and
extensively studied neurotransmitter [9]. For example, previous
studies have shown that approximately one third of autistic
children exhibited elevated blood levels of 5-HT, although this
relationship is less definitive in adult autistics [8,25]. Recently, a
positive correlation of 5-HT levels of platelet-poor plasma and the
brain has been shown in the rat autisitic model (rSey2/+) [26]. In
addition, SSRIs can improve repetitive behavior, which is one of
the core symptoms in ASDs [11]. Moreover, alterations in 5-HT
synthesis capacity have been observed in the brains of patients
with ASDs [27]. In this regard, recent studies on human genetics
have revealed that the 5-HT transporter (5-HTT, also named
SLC6A4) gene may contribute to increased risk for ASDs [28,29].
The behavioral and neurochemical phenotypes identified in this
study recapitulate those of animals deficient in 5-HTT or certain
5-HT receptors (e.g. 5-HT1A, 5-HT2C, and 5-HT7) [30–32].
Notably, 5-HTT2/2 mutant mice or rats exhibit various
behavioral defects that are similar to the phenotypes of patDp/+
mice, such as decreased exploratory activity in the open field test,
decreased marble burying behavior, lower basal activity in their
home cages, and increased latency to feed in the novelty
suppressed feeding test [33–38]. Interestingly, 5-HTT2/2 mice
also display less sociability and perseverance-like behaviors
[37–39]. Moreover, 5-HTT mutations also result in approximately
70% reductions in levels of brain intracellular 5-HT [35,40]. The
similarity of these phenotypic and neurochemical findings to the
results of the present study supports the hypothesis that
disturbances in serotonergic signaling at early developmental
stages might contribute to the behavioral phenotypes of patDp/+
mice.
MBII-52 is a small nucleolar RNA that is located within the
15q11-13 region and is a regulator of 5-HT2C receptor (5-HT2CR)
mRNA post-transcriptional modifications. We have previously
shown that MBII-52 is expressed at a two-fold higher level in the
brains of patDp/+ mice than WT mice. Furthermore, this increase
in expression of MBII-52 had functional relevance because it
increased intracellular calcium levels in neurons of patDp/+ mice
in response to a specific 5-HT2CR agonist, measured using an in
vitro microspectrofluorimetric technique [13]. Whether MBII-52
regulates 5-HT2CR function in vivo remains to be determined as
the editing ratio can be influenced by brain region and mouse
strain specificities [41]. Although more work on the relationship
between MBII-52 and RNA editing of the 5-HT2CR in vivo is
required, several lines of evidence suggest that the 5-HT2CR can
inhibit 5-HT neuronal activity and neurotransmission when
expressed on GABAergic interneurons in the dorsal raphe nucleus,
which are important modulators of 5-HT neurons [42–44]. Thus,
patDp/+ mice might have impaired local circuitry in the dorsal
Table 1. Tissue levels of monoamines in adult WT and patDp/+ mice.
Region and
genotype
5-HT
(pg/mg protein)
5-HIAA
(pg/mg protein)
5-HT turnover
(5-HIAA/5-HT)
DA
(pg/mg protein)
DOPAC
(pg/mg protein)
NE
(pg/mg protein)
Cerebellum
WT 800.89651.09 610.68±32.47 0.7860.05 91.3265.54 35.6765.26 2988.23671.28
patDp/+ 747.14654.16 533.36±13.65* 0.7460.05 85.9962.69 31.2061.47 2912.16644.96
Midbrain
WT 5723.94±181.88 4670.96±135.58 0.8260.03 2113.13662.56 695.06626.39 4731.576105.54
patDp/+ 5051.83±173.53* 4089.1±139.51* 0.8260.04 2985.016931.77 808.406193.80 4688.496131.68
Olfactory bulb
WT 4660.38±104.9 2015.87±145.69 0.4460.04 2630.636113.94 770.08653.47 3111.666100.50
patDp/+ 4266.45±142.64* 1590.04±57.23* 0.3860.02 2622.95650.96 709.17645.87 3244.77663.60
Prefrontal cortex
WT 7093.566142.73 1690.35(60.42 0.24(0.01 3208.95(1083.73 540.37(88.40 5771.15(123.21
patDp/+ 6846.74(102.99 1546.28(57.71 0.23(0.01 2151.43(595.04 373.67(60.14 5545.47(85.69
Pons and medulla
WT 4405.72(649.21 4354.89(294.4 1.28(0.24 1070.44(170.95 339.01(34.75 6086.68(204.58
patDp/+ 4359.11(620.47 4148.24(160.09 1.21(0.21 1041.80(149.70 337.42(20.21 6487.35(199.50
Values are means (SEM (n=10, each genotype).
Difference between genotypes is noted
*p,0.05 by t-test.
doi:10.1371/journal.pone.0015126.t001
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in patDp/+ mice.
Comprehensive quantification of monoamines also revealed
increased DA signaling during developmental stages that may be
relevant to the behavioral phenotypes of patDp/+ mice. Many of
the various functions and molecular pathways of DA in the mature
brain have been reported [45]. However, recent studies reported
biogenic amines including DA appear early during embryogenesis,
before the onset of synaptogenesis, suggesting that they may play
important roles in brain development [46]. In vitro studies
demonstrated that during brain development DA acts as a
promoter and an inhibitor of the number or length of branching
neurites [47,48]. Furthermore, DA signaling at earlier develop-
mental stages may contribute to postnatal neurogenesis and
migration of inhibitory interneurons [49–51]. As such, alterations
in DA signaling during development might also result in the
behavioral and neurochemical abnormalities in patDp/+ mice.
In this study, we quantified tissue monoamine levels. Future
studies should quantify extracellular monoamine levels using
microdialysis procedures, and determine whether these abnormal-
ities result from alterations in neurotransmitter release, reuptake,
or synthesis. Furthermore, a precise analysis at a nuclear level,
such as the raphe nucleus, would be informative. Such a precise
study on 5-HT and DA levels at the neural circuit level would be
necessary to decipher the neurochemical basis of abnormal
behaviors in patDp/+ mice. Additionally, investigations of
Figure 7. patDp/+ mice have decreased tissue 5-HT and increased tissue DA levels during postnatal development. Tissue levels of 5-
HT, 5-HIAA, 5-HIAA/5-HT, DA, DOPAC and HVA in mice during the described developmental stages in the cerebellum (Ce), cerebral cortex (Ctx),
hippocampus (Hip), hypothalamus (Hyp), midbrain (Mid), and pons and medulla (Pons). In WT mice, N =18–19 for postnatal (PND) 1 week old, 9–11
for PND 2 weeks old, and 7–14 for PND 3 weeks old. In patDp/+ mice, N=10–11 for PND 1 week old, 7–8 for PND 2 weeks old, and 4–8 for PND 3
weeks old. Error bars indicate SEM. *, p,0.05 (genotype effect).
doi:10.1371/journal.pone.0015126.g007
Decreased Activity and 5-HT in patDp/+ Mice
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for understanding when abnormalities of the 5-HT or DA
pathways begin.
The results of the present study demonstrate behavioral and
neurochemical abnormalities in patDp/+ mice backcrossed to the
C57BL/6J strain. These animals displayed lower locomotor/
exploratory activity in most of the activity-related behavioral tests
studied, and showed decreased 5-HT levels in several brain
regions during development and at adulthood. We also found that
tissue levels of DA and its metabolites were increased during
development. Based on these findings, we propose that alterations
in the serotonergic system at an early stage may contribute to
abnormal behavioral phenotypes in adult patDp/+ mice.
Materials and Methods
Animals and Experimental Design
We generated patDp/+ mice as previously described [13]. They
were bred for more than 10 generations on a C57BL/6J
background. They were housed as a pair of 1 WT and 1 patDp/
+ mouse or 2 pairs of WT and patDp/+ mice in a room with a 12-
hour light/dark cycle (light on 7:00 a.m. and off 7:00 p.m.). All
mice had access to food and water ad libitum. All experimental mice
were male patDp/+ ones, and age-matched (9–13 weeks old when
behavioral experiments were started) WT littermates were used as
controls. Twenty-two mice of each genotype were used for general
health and neurological screens, neuromuscular examinations,
light/dark transition test, open field test, elevated plus maze test,
hotplate test, rotarod test, marble burying test, prepulse inhibition
test, Y-maze test, tail suspension test, and contextual and cued fear
conditioning test in the described order. All behavioral experi-
ments were performed during the light phase (between 9:00 a.m.
and 6:00 p.m.). Additionally, the numbers of 13–14 mice in each
genotype were used for the novelty suppressed feeding test. For the
home cage behavioral assay, 4 WT and 9 patDp/+ mice were used.
Finally, 10 adult mice of each genotype and 4–19 mice in each
developmental stage of each genotype were used for HPLC
analysis. The experimental procedures and housing conditions for
animals were approved by the Animal Research Committee of
Osaka Bioscience Institute (08-304) and the Committee of Animal
Experimentation, Hiroshima University (A10-74). All efforts were
made to minimize suffering during and after all surgeries.
General health and neurological screen (GHNS)
A general health and neurological screen was conducted as
previously described [52]. The righting, whiskers touch, and ear
twitch reflexes were evaluated, and a number of physical features,
including body weight, body temperature, and the presence of
whiskers or bald hair patches, were recorded.
Neuromuscular examination
Neuromuscular strength was examined by the grip strength and
wire-hanging tests. The grip strength meter (O’Hara & Co.,
Tokyo, Japan) was used to assess forelimb grip strength. Mice were
lifted and held by their tail so that they could grasp a wire grid
with their forepaws. Mice were then gently pulled backward by the
tail with their posture parallel to the surface of the table until they
released the grid. The peak forelimb grip force applied by the mice
was recorded in Newtons [19]. Each mouse was tested three times
and the greatest value measured was used for statistical analysis. In
the wire hang test, mice were placed on a wire mesh that was then
inverted and waved gently, so that the subject gripped the wire.
Latency to fall within 60 sec was recorded by counting manually.
Light/dark transition test
The apparatus used for light/dark transition test consisted of a
cage (21642625 cm) divided into two sections of equal size by a
partition with a door (O’Hara & Co.) [53]. One section was
brightly illuminated (390 lux), whereas the other section was dark
(2 lux). Mice were placed into the dark side of the apparatus, and
allowed to move freely between the two sections for 10 min, while
the door remained open. The total number of transitions, time
spent in each section, initial latency to the light section, and
distance traveled were recorded automatically using Image LD
software. On-line material describing this method is available [53].
Open field test
Locomotor activity was measured using an open field test. Each
subject was allowed to move freely in the open field apparatus
(40640630 cm; Accuscan Instruments, Columbus, OH, USA)
equipped with photocells (beam spacing 2.5 cm, beam diameter
4 mm, beam frequency 50 cycles/s). Total distance traveled,
vertical activity (rearing measured by counting the number of
photobeam interruptions), time spent in the center area of the
open field, and stereotypic counts were recorded using the
VersaMax system (Accuscan Instruments). The center area was
defined as an inner section 1 cm away from each of the walls. If
the beam at the edge of the open field, 1 cm apart from the wall,
was not interrupted, mice were considered to be in the center area.
If a mouse broke the same beam (or set of beams) repeatedly, it
was considered to be exhibiting stereotypic activity. This activity is
often observed during grooming or head bobbing behaviors.
Stereotypic counts are the number of beam breaks that occur
during any period of stereotypic activity. Data were collected for
120 min.
Elevated plus maze test
The elevated plus maze consisted of two open arms (2565 cm)
and two enclosed arms of the same size, with 15 cm high
transparent walls. The arms and central square were made of
white plastic plates, and were elevated to a height of 55 cm above
the floor. To minimize the likelihood of animals falling from the
apparatus, 3-mm high Plexiglas ledges surrounded the open arms.
Arms of the same type were arranged at opposite sides to each
other. Each mouse was placed in the central square of the maze
(565 cm) facing one of the enclosed arms. Time spent in each arm
was recorded during the 10-min test period. Data acquisition and
analysis were performed automatically using Image EP software.
Hot plate test
The hot plate test was used to evaluate nociception. Mice were
placed on a 55.060.3uC hot plate (Columbus Instruments,
Columbus, OH, USA) and latency to the first hindpaw response
was recorded by counting manually. The hindpaw response was
either a foot shake or a paw lick. Each mouse is tested once.
Rotarod test
Motor coordination and balance were tested using the rotarod
test. This test was performed by placing a mouse on a rotating
drum (3 cm diameter; Accelerating Rotarod, UGO Basile, Varese,
Italy) and measuring the latency (seconds) of each subject to fall
from the rod. Six trials were performed and the speed of the
rotarod was increased from 4 to 40 rpm over a 5-min period.
Marble burying behavior test
Mice were individually placed in transparent polycarbonate
cages (1262769 cm) with a 5-cm layer of fine bedding material
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number of buried marbles and the total distance traveled were
recorded with a video camera for 30 min. When half of the marble
was in the fine bedding material, it was operationally defined as
buried. Three WT mice jumped out of the test cage during this test
and were omitted from subsequent data analysis.
Startle response/prepulse inhibition tests
Startle responses and prepulse inhibition of the startle responses
were measured using an automatic startle reflex measurement
system (O’Hara & Co.). A test session began by placing a mouse in
a Plexiglas cylinder, and left undisturbed for 10 min. The startle
stimulus was a broadband white noise that lasted 40 msec for all
trial types and the startle response was recorded during this time
period (measuring the response every 1 msec) without the prepulse
stimulus. The prepulse inhibition response was recorded for 140
msec starting with the onset of the prepulse stimulus. The
background noise level in each chamber was 70 dB. The peak
startle amplitude recorded during the 140 msec sampling window
was used as the dependent variable. A test session consisted of 6
trial types (i.e. two types for startle stimulus only trials, and four
types for prepulse inhibition trials). The intensity of the startle
stimulus was 110 or 120 dB. The prepulse was presented 100 msec
before the startle stimulus with an intensity of 74 or 78 dB. Four
combinations of prepulse and startle stimuli were employed (74–
110, 78–110, 74–120, and 78–120). Six blocks of the 6 trial types
were presented in pseudorandom order, such that each trial type
was presented once within a block. The average intertrial interval
was 15 sec (range: 10–20 sec).
Y-maze test
Exploratory activity was measured using a Y-maze apparatus
(arm length: 40 cm, arm bottom width: 3 cm, arm upper width:
10 cm, height of wall: 12 cm). Each subject was placed in the
center of the Y-maze field. The number of entries and alterations
were recorded using a modified version of the Image EP program.
Data were collected for 10 min.
Tail suspension test
The tail suspension test was performed following previously
described procedures [54]. Mice were suspended 30 cm above the
floor in a visually isolated area by adhesive tape placed
approximately 1 cm from the tip of the tail. Their behavior was
recorded over a 10 min test period. Data acquisition and analysis
were performed automatically using Image TS software. A single
WT and a single patDp/+ mouse fell from the adhesive tape and
their data were omitted from subsequent analysis.
Contextual and cued fear conditioning
Each mouse was placed in a test chamber (26634629 cm)
within a larger sound-attenuated chamber (O’Hara & Co.) and
allowed to explore freely for 2 min. A 60 dB white noise, which
served as the conditioned stimulus (CS), was presented for 30 sec.
Next, a mild (2 sec, 0.5 mA) foot shock, which served as the
unconditioned stimulus (US), was presented immediately after the
CS. Two more CS-US pairings were presented with a 2 min
interstimulus interval. Context testing was conducted 24 h after
conditioning in the same chamber. Cued testing with altered
context was conducted after conditioning using a triangular box
(35635640 cm) made of white opaque Plexiglas, which was
located in a different room [55]. Data acquisition, control of
stimuli (i.e. tones and shocks), and data analysis were performed
automatically using Image FZ software. Images were captured at 1
frame per sec. For each pair of successive frames, the amount of
area (in pixels) the mouse moved was measured. When this area
was below 20 pixels, the behavior was operationally defined as
‘freezing’. When the amount of area equaled or exceeded the
threshold, the behavior was defined as ‘non-freezing’. The optimal
threshold (amount of pixels) for determining freezing versus non-
freezing was calibrated to human observation of the behavior.
Freezing that lasted less than 2 sec was not included in the
analysis.
Novelty suppressed feeding test
This test was performed according to the previous study [56]
with some modifications. Twenty-four hours before the test, each
mouse was weighed and then deprived of all food in their home
cage. Prior to test, a food pellet was placed on a round filter paper
(10 cm) and positioned in the center of the apparatus
(40640640 cm). The subject mice were weighed again and the
difference of body weight loss was assessed. The test began
immediately after each subject was placed in the corner of the
apparatus and latency to feed the pellet was measured by counting
manually. The cutoff time of this test was set to 5 min.
Immediately, after attempting to feed or 5 min, each subject was
transferred to its home cage and the amount of food eaten was
measured by weighing pre- and post fed food pellet for 5 min to
evaluate their appetite.
Circadian rhythms of locomotor activity
Circadian rhythms of locomotor activity were analyzed as
previously described [57]. Each mouse was individually housed for
2 weeks in a 12 hour light-dark cycle condition (LD), and then for
2 weeks in constant darkness (DD). Locomotor activities were
monitored with an infrared locomotor recording apparatus
(Biotex, Kyoto, Japan) by recording activity in 1-min bins. The
data from the final week of LD were used to calculate spontaneous
activities of patDp/+ and WT mice. Circadian period was
estimated in each mouse from the last 5 days of locomotor
activity under DD.
Monoamine quantification in brain tissues
Tissue concentrations of biogenic monoamines were analyzed
after dissection in various brain regions, depending on the age of
the mouse. In adults, monoamines were measured in the
cerebellum (Ce), midbrain (Mid), olfactory bulb (OB), prefrontal
cortex (PFC), and pons and medulla (Pons). In young mice,
monoamines were analyzed in the Ce, Mid, Pons, cerebral cortex
(Ctx), hippocampus (Hip), and hypothalamus (Hyp). Brain tissue
was homogenized in 0.2 M ice-cold perchloric acid and the
homogenates were cooled on ice for 30 min to deproteinize. The
homogenates were centrifuged at 20,0006 g for 15 min at 0uC.
Then, the pH of the supernatant was adjusted to approximately
3.0 by adding 1 M sodium acetate, and the precipitate was used
for protein quantification. The samples were filtered through a
0.45 mm filter (Millipore, Billerica, MA, USA) and centrifuged at
5006g for 15 min at 4uC. Next, 30–40 ml of filtrate was loaded
into a high performance liquid chromatography (HPLC) system
(Eicom, Kyoto, Japan). The HPLC system had a 15063m m
octadecyl silane column (SC-5ODS, Eicom), and an electrochem-
ical detector (HTEC-500, Eicom) set to an applied potential of
+750 mV versus an Ag/AgCl reference analytical electrode. The
change in electric current (nA) was recorded using a computer
interface. The mobile phase was composed of aceto-citric acid
buffer (pH 3.5, 0.1 M), methanol, sodium-1-octane sulfonate
(0.46 M), and disodium ethylenediaminetetraacetic acid
(0.015 mM) [830: 170: 1.9: 1]. The flow rate was 0.5 ml/min.
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according to manufacturer’s protocol (Sigma, St. Louis, MO,
USA).
Data analysis
Behavioral data were obtained automatically by customized
(O’Hara & Co.) applications that were based on a public domain
NIH Image program and the ImageJ program. Statistical analysis
was conducted using StatView Ver 5.0 (SAS Institute, Cary, NC,
USA). Data were analyzed by two-way analysis of variance
(ANOVA), two-way repeated-measures ANOVA, or unpaired t-
test. Unless otherwise noted, the F and p values are for the
genotype effect. The criterion for significance was set at p,0.05.
Kaplan-Meier survival analysis was used to analyze data from the
novelty suppressed feeding test because these data did not have a
normal distribution. Mantel-Cox log rank test was used to evaluate
differences between genotypes in this test.
Supporting Information
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